Stay Curious

SIGN UP FOR OUR WEEKLY NEWSLETTER AND UNLOCK ONE MORE ARTICLE FOR FREE.

Sign Up

VIEW OUR Privacy Policy


Discover Magazine Logo

WANT MORE? KEEP READING FOR AS LOW AS $1.99!

Subscribe

ALREADY A SUBSCRIBER?

FIND MY SUBSCRIPTION
Advertisement

First Human Test of Optogenetics Could Restore Sight to the Blind

Discover how optogenetics could restore vision for patients with retinitis pigmentosa through groundbreaking gene therapy in clinical trials.

Newsletter

Sign up for our email newsletter for the latest science news

Sign Up

(Credit: Victoria Shapiro/Shutterstock) A decade-old technique that allows researchers to control brain function in lab animals could partially restore sight to the blind. In a trial sponsored by RetroSense Therapeutics, a startup company in Ann Arbor, Michigan, doctors will inject a harmless virus loaded with DNA from photoreceptive algae into the eyes of 15 patients suffering from retinitis pigmentosa. The experimental procedure represents the first human test of optogenetics, which is a technique that genetically modifies neurons to make them responsive to light. Doctors from the Retina Foundation of the Southwest will perform the procedure, and attempt to transfer the job duties of photoreceptor cells to different cells in the eye to restore sight.

Before our brains build a visual image of our world, a chain of cells in our eyes must convert light into electrical signals that are processed in the brain. Photoreceptor cells in the retina represent the ...

Stay Curious

JoinOur List

Sign up for our weekly science updates

View our Privacy Policy

SubscribeTo The Magazine

Save up to 40% off the cover price when you subscribe to Discover magazine.

Subscribe
Advertisement

0 Free Articles